Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VINIA is a patented dietary supplement composed of red grape cell powder, delivering a matrix of polyphenols including Piceid Resveratrol, catechins, quercetins, anthocyanins, and tannins. The product is designed to support cardiovascular health by increasing arterial dilation and improving blood flow through a dual mechanism—boosting nitric oxide (NO) production (a vasodilator) and reducing endothelin-1 (ET-1) levels (a vasoconstrictor). Clinical studies have shown that daily use of VINIA increases arterial dilation by at least 70% over three months. The supplement features high bioavailability with rapid absorption into the bloodstream within 20 minutes and sustained activity for up to 12 hours. Developed using proprietary technology to preserve the original structure of Piceid Resveratrol from red grapes, VINIA is marketed as gluten-free, dairy-free, plant-based, non-GMO, and contains no alcohol or significant calories or sugars. It is not intended for children[2][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VINIA.